Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Phase Ii ◽

Triple Negative ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-016-1195-6 ◽

2016 ◽

Vol 17 (1) ◽

Author(s):

Denise A. Yardley ◽

Adam Brufsky ◽

Robert E. Coleman ◽

Pierfranco F. Conte ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.01.065 ◽

2021 ◽

Author(s):

A. Brufsky ◽

S.B. Kim ◽

Ž. Zvirbule ◽

A. Eniu ◽

J. Mebis ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Triple Negative ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Primary Analysis ◽

OT3-01-08: Phase II Study of S-1 Combined with Cisplatin in the First-Line Treatment of Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-08 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-016-1423-0 ◽

2016 ◽

Vol 17 (1) ◽

Cited By ~ 7

Author(s):

Philip C. Schouten ◽

Gwen M. H. E. Dackus ◽

Serena Marchetti ◽

Harm van Tinteren ◽

Gabe S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Phase Ii Trial ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

Randomized Phase Ii ◽

tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps1146 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS1146-TPS1146 ◽

Cited By ~ 1

Author(s):

Denise A. Yardley ◽

Adam Brufsky ◽

Robert E. Coleman ◽

Pier Franco Conte ◽

Javier Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

TRYbeCA-2: A randomized phase II/III study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz242.076 ◽

2019 ◽

Vol 30 ◽

pp. v138

Author(s):

A.H. Awada ◽

J. Cortés ◽

S. Slater ◽

I. Macpherson ◽

T. Csoszi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Locally Recurrent ◽

P5-19-04: Results of a Randomized Phase II Study Demonstrate Benefit of Platinum-Based Regimen in the First-Line Treatment of Triple Negative Breast Cancer (TNBC).

10.1158/0008-5472.sabcs11-p5-19-04 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu ◽

P Yuan ◽

JY Wang ◽

F Ma ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

10.1158/1538-7445.sabcs16-ot3-04-01 ◽

2017 ◽

Author(s):

B Schneider ◽

KD Miller ◽

S Badve ◽

B O'Neil ◽

P Helft ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Triple Negative ◽

Controlled Trial ◽

Randomized Controlled

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Clinical Breast Cancer ◽

10.1016/j.clbc.2018.12.008 ◽

2019 ◽

Vol 19 (2) ◽

pp. e283-e296 ◽

Cited By ~ 7

Author(s):

Lynn Symonds ◽

Hannah Linden ◽

Vijayakrishna Gadi ◽

Larissa Korde ◽

Eve Rodler ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapy ◽

Phase Ii ◽

Targeted Therapies ◽

Triple Negative ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

P-228 Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m + mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease

Annals of Oncology ◽

10.1016/j.annonc.2021.05.282 ◽

2021 ◽

Vol 32 ◽

pp. S177

Author(s):

D. Paez ◽

F. Gomez ◽

J. Maurel ◽

A. Virgili ◽

V. Baños ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Poor Prognosis ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Limited Disease ◽

Randomized Controlled ◽